Cell cycle genes in a mouse mammary hyperplasia model

Journal of Mammary Gland Biology and Neoplasia

Volumn 9, Issue 1, 2004, Pages 81-93

  Said, Thenaa K ^a   Medina, Daniel ^a  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

Cell cycle genes; Cell cycle profile; Mammary gland; Mammary hyperplasia; Mouse mammary hyperplasia model

Indexed keywords

CELL CYCLE PROTEIN; CYCLIN D; CYCLIN DEPENDENT KINASE; CYCLIN E; DNA; PROTEIN P16; PROTEIN P21;

BREAST CANCER; BREAST HYPERPLASIA; CANCER STAGING; CELL CYCLE; CHROMOSOME ABERRATION; DISEASE MODEL; DNA SYNTHESIS; EPITHELIUM CELL; GENE ACTIVATION; GENE MUTATION; GENE SEQUENCE; NONHUMAN; PROTEIN EXPRESSION; REVIEW; SENESCENCE; TELOMERE;

ANIMALS; BREAST; BREAST NEOPLASMS; CELL CYCLE; CELL CYCLE PROTEINS; CHROMOSOME ABERRATIONS; CYCLIN-DEPENDENT KINASE INHIBITOR P27; CYCLINS; DISEASE MODELS, ANIMAL; DNA; EPITHELIAL CELLS; FEMALE; HUMANS; HYPERPLASIA; MAMMARY GLANDS, ANIMAL; MAMMARY NEOPLASMS, ANIMAL; MICE; TUMOR SUPPRESSOR PROTEINS;

EID: 4344646567     PISSN: 10833021     EISSN: None     Source Type: Journal    
DOI: 10.1023/B:JOMG.0000023590.63974.f8     Document Type: Review

References (115)

1. C. J. Sherr (1993). Mammalian G1 cyclins. Cell 73:1059-1065.
2. C. J. Sherr (1996). Cancer cell cycle. Science 274:1672-1677.
3. D. O. Morgan (1995). Principles of CDK regulation. Nature 374:131-134.
4. K.-I. Nakayama and K. Nakayama (1998). Cip/Kip cyclin-dependent kinase inhibitors: Brakes of the cell cycle engine during development. Bioessays 20:1020-1029.
5. C. J. Sherr and J. M. Roberts (1999). CDK inhibitors: Positive and negative regulators of G1-phase progression. Genes Dev. 13:1501-1512.
6. Y. Taya (1997). RB kinases and RB-binding proteins: New points of view. Trends Biochem. Sci. 22:14-17.
7. J. R. Nevins, G. Leone, J. DeGregori, and L. Jakoi (1997). Role of the Rb/E2F pathway in cell growth control. J. Cell. Physiol. 173:233-236.
8. S. Herwig and M. Strauss (1997). The retinoblastoma protein: A master regulator of cell cycle, differentiation and apoptosis. Eur. J. Biochem. 246:581-601.
9. A. Brehm, E. A. Miska, D. J. McCance, J. L. Reid, A. J. Bannister, and T. Kouzarides (1998). Retinoblastoma protein recruits histone deacetylase to repress transcription. Nature 391:597-601.
10. L. Magnaghi-Jaulin, R. Groisman, I. Naguibneva, P. Robin, S. Lorain, J. P. Le Villain, et al. (1998). Retinoblastoma protein represses transcription by recruiting a histone deacetylase. Nature 391:601-605.
11. R. X. Luo, A. A. Postigo, and D. C. Dean (1998). Rb interacts with histone deacetylase to repress transcription. Cell 92:463-473.
12. R. A. DePinho (1998). Transcriptional repression. The cancer-chromatin connection. Nature 391:533, 535-536.
13. T. A. Weinert and L. H. Hartwell (1988). The RAD9 gene controls the cell cycle response to DNA damage in Saccharomyces cerevisiae. Science 241:317-322.
14. J. Bartek and J. Lukas (2001). Mammalian G1- and S-phase checkpoints in response to DNA damage. Curr. Opin. Cell Biol. 13:738-747.
15. S. J. Elledge (1996). Cell cycle checkpoints: preventing an identity crisis. Science 274:1664-1672.
16. A. G. Paulovich, D. P. Toczyski, and L. H. Hartwell (1997). When checkpoints fail. Cell 88:315-321.
17. L. L. Sandell and V. A. Zakian, (1993). Loss of a yeast telomere: arrest, recovery, and chromosome loss. Cell 75:729-739.
18. L. H. Hartwell and M. B. Kastan (1994). Cell cycle control and cancer. Science 266:1821-1828.
19. D. W. Morris and R. D. Cardiff. (1987). The multistep model of mouse mammary tumor development. Adv. Viral Oncol. 7:123-40.
20. K. B. DeOme, L. J. Faulkin, Jr., H. A. Bern, and P. E. Blair (1959). Development of mammary tumors from hyperplastic alveolar nodules transplanted into gland-free mammary fat pads of female C3H mice. Cancer Res. 19:515-520.
21. D. Medina (1996). Hyperplasia of the mammary gland. In R. Dickson and M. Lippman, (eds). Mammary Tumor Cell Cycle, Differentiation and Metastasis, Kluwer Academic Publishers, Norwell, MA, pp. 36-69.
22. R. D. Cardiff, S. R. Wellings, L. J. Faulkin, Jr. (1977). Biology of Breast preneoplasia. Cancer 39:2734-2746.
23. R. D. Cardiff (1996). The biology of mammary transgenes: Five rules. J. Mam. Gland Neoplasia 1:61-73.
24. P. M. Siegel, W. R. Hardy, and W. J. Muller (2000). Mammary gland neoplasia: Insights from transgenic mouse models. Bioessays 22:554-563.
25. R. D. Cardiff and W. J. Muller (1993). Transgenic mouse models of mammary tumorigenesis. Cancer Surv. 16:97-113.
26. M. A. Webster and W. J. Muller (1994). Mammary tumorigenesis and metastasis in transgenic mice. Semin. Cancer Biol. 5:69-76.
27. C. X. Deng and S. G. Brodie (2001). Knockout mouse models and mammary tumorigenesis. Semin. Cancer Biol. 11:387-394.
28. A. C. Blackburn and D. J. Jerry (2002). Knockout and transgenic mice of Trp53: What have we learned about p53 in breast cancer? Breast Cancer Res. 4:101-111.
29. F. S. Kittrell, C. J. Oborn, and D. Medina (1992). Medina Development of mammary preneoplasias in vivo from mouse mammary epithelial cell lines in vitro. Cancer Res. 52:1924-1932.
30. D. Medina and F. S. Kittrell (1993). Immortalization phenotype dissociated from the preneoplastic phenotype in mouse mammary epithelial outgrowths in vivo. Carcinogenesis 14:25-28.
31. T. K. Said, R. C. Moraes, U. Singh, F. S. Kittrell, and D. Medina (2001). Cyclin-dependent kinase (cdk) inhibitors/cdk4/cdk2 complexes in early stages of mouse mammary preneoplasia. Cell Growth Differ. 12:285-295.
32. C. Jiang, L. Juo, T. K. Said, H. Thomson, and D. Medina (1997). Immortalized mouse mammary cells in vivo do not exhibit increased telomerase activity. Carcinogenesis 18:2085-2091.
33. T. K. Said and D. Medina (1995). Cell cycle and cyclin-dependent kinase activities in mouse mammary tumor development. Carcinogenesis 16:823-830.
34. R. D. Cardiff (1984). Protoneoplasia: the molecular biology of mouse mammary hyperplasia. Adv. Cancer Res. 42:167-190.
35. R. Y. Poon, H. Toyoshima, and T. Hunter (1995). Redistribution of the CDK inhibitor p27 between different cyclin CDK complexes in the mouse fibroblast cell cycle and in cells arrested with lovastatin or ultraviolet irradiation. Mol. Biol. Cell 6:1197-1213.
36. I. Perez-Roger, S. H. Kim, B. Griffiths, A. Sewing, and H. Land (1999). Cyclins D1 and D2 mediate myc-induced proliferation via sequestration of p27 (Kip1) and p21(Cip1). EMBO J. 18:5310-5320.
37. C. Bouchard, K. Thieke, A. Maier, R. Saffrich, J. Hanley-Hyde, W. Ansorge, et al. (1999). Direct induction of cyclin D2 by Myc contributes to cell cycle progression and sequestration of p27. EMBO J. 18:5321-5333.
38. M. Cheng, V. Sexl, C. J. Sherr, and M. F. Roussel (1998). Assembly of cyclin D-dependent kinase and titration of p27Kip1 regulated by mitogen-activated protein kinase kinase (MEK1). Proc. Natl. Acad. Sci. US.A. 95:1091-1096.
39. G. Kong, S. S. Chua, Y. Yijun, F. Kittrell, R. C. Moraes, D. Medina, et al. (2002). Functional analysis of cyclin D2 and p27 (Kip1) in cyclin D2 transgenic mouse mammary gland during development. Oncogene 21:7214-7225.
40. P. Sicinski and R. A. Weinberg (1997). A specific role for cyclin D1 in mammary gland development. J. Mam. Gland Biol. Neoplasia 2:335-242.
41. D. M. Barnes and C. E. Gillett (1998). Cyclin D1 in breast cancer. Breast Cancer Res. Treat. 52:1-15.
42. Q. Yu, Y. Geng, and P. Sicinski (2001). Specific protection against breast cancers by cyclin D1 ablation. Nature 411:1017-1021.
43. S. Kampfer, M. Windegger, F. Hochholdinger, W. Schwaiger, R. G. Pestell, G. Baier, et al. (2001). Protein kinase C isoforms involved in the transcriptional activation of cyclin D1 by transforming Ha-Ras. J. Biol. Chem. 276:42834-42842.
44. M. Sabbah, D. Courilleau, J. Mester, and G. Redeuilh (1999). Estrogen induction of the cyclin D1 promoter: Involvement of a cAMP response-like element. Proc. Natl. Acad. Sci. U.S.A. 96:11217-11222.
45. M. D. Planas-Silva, J. L. Donaher, and R. A. Weinberg (1999). Functional activity of ectopically expressed estrogen receptor is not sufficient for estrogen-mediated cyclin D1 expression. Cancer Res. 59:4788-4792.
46. T. K. Said, O. M. Conneely, D. Medina, B. W. O'Malley, and J. P. Lydon (1997). Progesterone, in addition to estrogen, induces cyclin D1 expression in the murine mammary epithelial cell, in vivo. Endocrinology 138:3933-3939.
47. O. Coqueret (2002). Linking cyclins to transcriptional control. Gene 299:35-55.
48. T. C. Wang, R. D. Cardiff, L. Zukerberg, E. Lees, A. Arnold, and E. V. Schmidt (1994). Mammary hyperplasia and carcinoma in MMTV-cyclin D1 transgenic mice. Nature 369:669-671.
49. J. M. Huard, C. C. Forster, M. L. Carter, P. Sicinski, and M. E. Ross (1999). Cerebellar histogenesis is disturbed in mice lacking cyclin D2. Development 126:1927-1935.
50. J. Lukas, J. Bartkova, M. Welcker, O. W. Petersen, G. Peters, M. Strauss, et al. (1995). Cyclin D2 is a moderately oscillating nucleoprotein required for G1 phase progression in specific cell types. Oncogene 10:2125-2134.
51. M. F. Buckley, K. J. Sweeney, J. A. Hamilton, R. L. Sini, D. L. Manning, R. I. Nicholson, et al. (1993). Expression and amplification of cyclin genes in human breast cancer. Oncogene 8:2127-2133.
52. S. W. Tam, A. M. Theodoras, J. W. Shay, G. F. Draetta, M. Pagano (1994). Differential expression and regulation of Cyclin D1 protein in normal and tumor human cells: Association with Cdk4 is required for Cyclin D1 function in G1 progression. Oncogene 9:2663-2674.
53. K. J. Sweeney, B. Sarcevic, R. L. Sutherland, E. A. Musgrove (1997). Cyclin D2 activates Cdk2 in preference to Cdk4 in human breast epithelial cells. Oncogene 14:1329-1340.
54. E. Evron, W. C. Dooley, C. B. Umbricht, D. Rosenthal, N. Sacchi, E. Gabrielson, et al. (2001). Detection of breast cancer cells in ductal lavage fluid by methylation-specific PCR. Lancet 357:1335-1336.
55. T. K. Said, L. Luo, and D. Medina (1995). Mouse mammary hyperplasias and neoplasias exhibit different patterns of cyclins D1 and D2 binding to cdk4. Carcinogenesis 16:2507-2513.
56. T. C. Wang, R. D. Cardiff, L. Zukerberg, E. Lees, A. Arnold, and E. V. Schmidt (1994). Mammary hyperplasia and carcinoma in MMTV-cyclin D1 transgenic mice. Nature 369:669-671.
57. A. Koff, A. Giordano, D. Desai, K. Yamashita, J. W. Harper, S. Elledge, et al. (1992). Formation and activation of a cyclin E-cdk2 complex during the G1 phase of the human cell cycle. Science 257:1689-1694.
58. C. Sherr and J. Roberts (1995). Inhibitors of mammalian G1 cyclin-dependent kinases. Gene Dev. 9:1149-1163.
59. G. D'Urso, R. L. Marraccino, D. R. Marshak, and J. M. Roberts (1990). Cell cycle control of DNA replication by a homologue from human cells of the p34cdc2 protein kinase. Science 250:786-791.
60. T. Hunter (1995). Breaking the cycle. Cell 75:839-841.
61. S. Elledge and J. Harper (1994). Cdks inhibitors: On the threshold of checkpoints and development. Curr. Opin. Cell Biol. 6:847-852.
62. M. D. Planas-Silva and R. A. Weinberg (1997). Estrogen-dependent cyclin-E-cdk2 activation through p21 redistribution. Mol. Cell. Biol. 17:4059-4069.
63. K. Keyomarsi and A. B. Pardee (1993). Redundant cyclin overexpression and gene amplification in breast cancer cells. Proc. Natl. Acad. Sci. US.A. 90:1112-1116.
64. K. Keyomarsi, N. O'Leary, G. Molnar, E. Lees, H. J. Fingert, A. B. Pardee, and (1994). Cyclin E. a potential prognostic marker for breast cancer. Cancer Res. 54:380-385.
65. D. C. Porter, N. Zhang, C. Danes, M. J. McGahren, R. M. Harwell, S. Faruki et al. (2001). Tumor-specific proteolytic processing of cyclin E generates hyperactive low-molecular-weight forms. Mol. Cell. Biol. 21:6254-6269.
66. K. Keyomarsi, S. L. Tucker, T. A. Buchholz, M. Callister, Y. Ding, G. N. Hortobagyi et al. (2002). Cyclin E and survival in patients with breast cancer. N. Engl. J. Med. 347:1566-1575.
67. W. Imagawa, J. Yang, R. Guzman, and S. Nandi (1994). In E. Knobil and J. D. Neill (eds.). Control of Mammary Gland Development. The Physiology of Reproduction, Raven Press, New York, pp. 1033-1063.
68. O. W. Prall, E. M. Rogan, and R. L. Sutherland (1998). Estrogen regulation of cell cycle progression in breast cancer cells. J. Steroid Biochem. Mol. Biol. 65:169-174.
69. S. Nandi, R. C. Guzman, and J. Yang (1995). Hormones and mammary carcinogenesis in mice, rats, and humans: a unifying hypothesis. Proc. Natl. Acad. Sci. U.S.A. 92:3650-3657.
70. C. L. Clarke and R. L. Sutherland (1990). Progestin regulation of cellular proliferation. Endocr. Rev. 11:266-300.
71. I. A. Forsyth (1991). The mammary gland. Baillieres Clin. Endocrinol. Metab. 5:809-832.
72. R. L. Sutherland, O. W. Prall, C. K. Watts, and E. A. Musgrove (1998). Estrogen and progestin regulation of cell cycle progression. J. Mam. Gland Biol. Neoplasia 3:63-72.
73. S. A. Aaronson, J. S. Rubin, P. W. Finch, J. Wong, C. Marchese, J. Falco, et al. (1990). Growth factor-regulated pathways in epithelial cell proliferation. Rev. Respir. Dis. 142:S7-S10.
74. M. N. Pollak (1998). Endocrine effects of IGF-I on normal and transformed breast epithelial cells: Potential relevance to strategies for breast cancer treatment and prevention. Breast Cancer Res. Treat. 47:209-217.
75. H. Kuhling, P. Alm, H. Olsson, M. Ferno, B. Baldetorp, and R. Parwaresch (2003). Expression of cyclins E, A, and B, and prognosis in lymph node-negative breast cancer. J. Pathol. 199:424-431.
76. K. L. Marsh and J. M. Varley (1998). Frequent alterations of cell cycle regulators in early-stage breast lesions as detected by immunohistochemistry. Br. J. Cancer 77:1460-1468.
77. Q. Zhou, T. Hopp, S. A. Fuqua, and P. S. Steeg (2001). Cyclin D1 in breast premalignancy and early breast cancer: Implications for prevention and treatment. Cancer Lett. 162:3-17.
78. J. Tsihlias, L. Kapusta, and J. Slingerland (1999). The prognostic significance of altered cyclin-dependent kinase inhibitors in human cancer. Annu. Rev. Med. 50:401-423.
79. J. N. Zhou and S. Linder (1996). Expression of CDK inhibitor genes in immortalized and carcinoma derived breast cell lines. Anticancer Res. 16:1931-1935.
80. D. Parry, D. Mahony, K. Wills, and E. Lees (1999). Cyclin D-CDK subunit arrangement is dependent on the availability of competing INK4 and p21 class inhibitors. Mol. Cell. Biol. 19:1775-1783.
81. B. B. McConnell, F. J. Gregory, F. J. Stott, E. Hara, and G. Peters (1999). Induced expression of p16(INK4a) inhibits both CDK4- and CDK2-associated kinase activity by reassortment of cyclin-CDK-inhibitor complexes. Mol. Cell. Biol. 19:1981-1989.
82. A. J. Brenner, M. R. Stampfer, and C. M. Aldaz (1998). Increased p16 expression with first senescence arrest in human mammary epithelial. Oncogene 17:199-205.
83. L. Xu, D. Sgroi, C. J. Sterner, R. L. Beauchamp, D. M. Pinney, S. Keel, et al. (1994). Mutational analysis of CDKN2 (MTS1/p16ink4) in human breast carcinomas. Cancer Res. 54:5262-5264.
84. U. Lehmann, F. Langer, H. Feist, S. Glockner, B. Hasemeier, and H. Kreipe (2002). Quantitative assessment of promoter hypermethylation during breast cancer development. Am. J. Pathol. 160:605-612.
85. W. S. el-Deiry, T. Tokino, V. E. Velculescu, D. B. Levy, R. Parsons, J. M. Trent, et al. (1993). WAF1, a potential mediator of p53 tumor suppression. Cell 75:817-825.
86. J. W. Harper, G. R. Adami, N. Wei, K. Keyomarsi, and S. J. Elledge (1993). The p21 Cdk-interacting protein Cip1 is a potent inhibitor of G1 cyclin-dependent kinases. Cell. 75:805-816.
87. Y. Gu, C. W. Turck, and D. O. Morgan (1993). Inhibition of CDK2 activity in vivo by an associated 20K regulatory subunit. Nature 366:707-710.
88. A. W. Murray (1995). The genetics of Cell cycle checkpoints. Curr. Opin. Genet. Dev. 5:5-11.
89. A. L. Gartel and A. L. Tyner (2002). The role of the cyclin-dependent kinase inhibitor p21 in apoptosis. Mol. Cancer Ther. 1:639-649.
90. D. J. Jerry, C. Kuperwasser, S. R. Downing, J. Pinkas, C. He, E. Dickinson, et al. (1998) Delayed involution of the mammary epithelium in BALB/c-p53null mice. Oncogene 17:2305-2312.
91. M. J. Rey, P. L. Fernandez, P. Jares, M. Munoz, A. Nadal, N. Peiro, et al. (1998). p21WAF1/Cip1 is associated with cyclin D1CCND1 expression and tubular differentiation but is independent of p53 overexpression in human breast carcinoma. J. Pathol. 184:265-271.
92. S. Rao, M. Lowe, T. W. Herliczek, and K. Keyomarsi (1998). Lovastatin mediated G1 arrest in normal and tumor breast cells is through inhibition of CDK2 activity and redistribution of p21 and p27, independent of p53. Oncogene 17:2393-2402.
93. R. S. Alpan and A. B. Pardee (1996). p21WAF1CIP1/SDI1 is elevated through a p53-independent pathway by mimosine. Cell Growth Differ. 7:893-901.
94. R. S. Chapman, P. C. Lourenco, E. Tonner, D. J. Flint, S. Selbert, K. Takeda, et al. (1999). Suppression of epithelial apoptosis and delayed mammary gland involution in mice with a conditional knockout of Stat3. Genes Dev. 13:2604-2616.
95. J. LaBaer, M. D. Garrett, L. F. Stevenson, J. M. Slingerland, C. Sandhu, H. S. Chou, et al. (1997). New functional activities for the p21 family of CDK inhibitors. Genes Dev. 11:847-862.
96. S. F. Doisneau-Sixou, C. M. Sergio, J. S. Carroll, R. Hui, E. A. Musgrove, and R. L. Sutherland (2003). Estrogen and antiestrogen regulation of cell cycle progression in breast cancer cells. Endocr. Relat. Cancer 10:179-186.
97. Y. L. Oh, J. S. Choi, S. Y. Song, Y. H. Ko, B. K. Han, S. J. Nam, et al. (2001). Expression of p21 Wafl, p27Kip1 and cyclin D1 proteins in breast ductal carcinoma in situ: Relation with clinicopathologic characteristics and with p53 expression and estrogen receptor status. Pathol. Int. 51:94-99.
98. M. Barbareschi, O. Caffo, C. Doglioni, P. Fina, A. Marchetti, F. Buttitta, et al. (1996). p21WAF1 immunohistochemical expression in breast carcinoma: Correlations with clinicopathological data, oestrogen receptor status, MIB1 expression, p53 gene and protein alterations and relapse-free survival. Br. J. Cancer 74:208-215.
99. J. Lukas, S. Groshen, B. Saffari, N. Niu, A. Reles, W. H. Wen, et al. (1997). WAF1/Cip1 gene polymorphism and expression in carcinomas of the breast, ovary, and endometrium. Am. J. Pathol. 150:167-175.
100. A. Koff, M. Ohtsuki, K. Polyak, J. M. Roberts, and J. Massague (1993). Negative regulation of G1 in mammalian cells: Inhibition of cyclin E-dependent kinase by TGF-beta. Science 260:536-539.
101. J. M. Slingerland, L. Hengst, C. H. Pan, D. Alexander, M. R. Stampfer, and S. I. Reed (1994). A novel inhibitor of cyclin-CDK activity detected in transforming growth factor beta-arrested epithelial cells. Mol. Cell. Biol. 14:3683-3694.
102. J. C. Donovan, J. M. Rothenstein, and J. M. Slingerland (2002). Non-malignant and tumor-derived cells differ in their requirement for p27Kip1 in transforming growth factor-beta-mediated G1 arrest. J. Biol. Chem. 277:41686-41692.
103. St. B. Croix, C. Sheehan, J. W. Rak, V. A. Florenes, J. M. Slingerland, and R. S. Kerbel (1998). E-Cadherin-dependent growth suppression is mediated by the cyclin-dependent kinase inhibitor p27(KIP1). J. Cell Biol. 142:557-571.
104. J. Tsihlias, L. Kapusta, and J. Slingerland (1999). The prognostic significance of altered cyclin-dependent kinase inhibitors in human cancer. Annu. Rev. Med. 50:401-423.
105. M. Barbareschi (1999). p27 Expression, a cyclin dependent kinase inhibitor in breast carcinoma. Adv. Clin. Pathol. 3:119-127.
106. R. Chiarle, M. Pagano, and G. Inghirami (2001). The cyclin dependent kinase inhibitor p27 and its prognostic role in breast cancer. Breast Cancer Res. 3:91-94.
107. C. Catzavelos, N. Bhattacharya, Y. C. Ung, J. A. Wilson, L. Roncari, and C. Sandhu, (1997). Decreased levels of the cell-cycle inhibitor p27Kip1 protein: Prognostic implications in primary breast cancer. Nat. Med. 3:227-230.
108. M. Loden, N. H. Nielsen, G. Roos, S. O. Emdin, and G. Landberg (1999). Cyclin E dependent kinase activity in human breast cancer in relation to cyclin E, p27 and p21 expression and retinoblastoma protein phosphorylation. Oncogene 18:2557-2566.
109. G. Viglietto, M. L. Motti, P. Bruni, R. M. Melillo, A. D'Alessio, D. Califano, et al. (2002). Cytoplasmic relocalization and inhibition of the cyclin-dependent kinase inhibitor p27(Kip1) by PKB/Akt-mediated phosphorylation in breast cancer. Nat. Med. 8:1136-1144.
110. I. Shin, F. M. Yakes, F. Rojo, N. Y. Shin, A. V. Bakin, J. Baselga, et al. (2002). PKB/Akt mediates cellcycle progression by phosphorylation of p27(Kip1) at threonine 157 and modulation of its cellular localization. Nat. Med. 8:1145-1152.
111. J. Liang, J. Zubovitz, T. Petrocelli, R. Kotchetkov, M. K. Connor, K. Han, et al. (2002). PKB/Akt phosphorylates p27, impairs nuclear import of p27 and opposes p27-mediated G1 arrest. Nat. Med. 8:1153-1160.
112. S. F. Doisneau-Sixou, C. M. Sergio, J. S. Carroll, R. Hui, E. A. Musgrove, and R. L. Sutherland (2003). International Congress on Hormonal Steroids and Hormones and Cancer: Estrogen and antiestrogen regulation of cell cycle progression in breast cancer cells. Endocr. Relat. Cancer 10:179-186.
113. J. Adams, V. J. Palombella, E. A. Sausville, J. Johnson, A. Destree, D. D., Lazarus, et al. (1999). Proteasome inhibitors: A novel class of potent and effective antitumor agents. Cancer Res. 59:2615-2622.
114. J. Adams, V. J. Palombella, and P. J. Elliott (2000). Proteasome inhibition: A new strategy in cancer treatment. Invest. New Drugs 18:109-121.
115. H.-J. Lenz (2003). Clinical update: Protesome inhibitors in solid tumors. Cancer Treat. Rev. 29:41-48.